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Abstract 
 
Acute radiation cystitis occurs during or soon after radiation treatment. It is usually self-limiting, and 
is generally managed conservatively. Late radiation cystitis, on the other hand, can develop from 6 
months to 20 years after radiation therapy. The main presenting symptom is hematuria, which may 
vary from mild to severe, life-threatening hemorrhage. Initial management includes intravenous fluid 
replacement, blood transfusion if indicated and transurethral catheterization with bladder washout 
and irrigation. Oral or parenteral agents that can be used to control hematuria include conjugated 
estrogens, pentosan polysulfate or WF10. Cystoscopy with laser fulguration or electrocoagulation of 
bleeding points is sometimes effective. Injection of botulinum toxin A in the bladder wall may relieve 
irritative bladder symptoms. Intravesical instillation of aluminum, placental extract, prostaglandins or 
formalin can also be effective. More-aggressive treatment options include selective embolization or 
ligation of the internal iliac arteries. Surgical options include urinary diversion by percutaneous 
nephrostomy or intestinal conduit, with or without cystectomy. Hyperbaric oxygen therapy (HBOT) 
involves the administration of 100% oxygen at higher than atmospheric pressure. The reported 
success rate of HBOT for radiation cystitis varies from 60% to 92%. An important multicenter, double-
blind, randomized, sham-controlled trial to evaluate the effectiveness of HBOT for refractory 
radiation cystitis is currently being conducted. 
 
Introduction 
Radiation can be defined as the emission of energy by one body, its transmission through an 
intervening medium and its absorption by another body. The term 'radiation' refers to an 
electromagnetic spectrum that comprises, amongst others, alpha, beta and gamma particles. Gamma 
particles (X-rays) emit high-energy radiation, and can be used for therapeutic benefit.1 
Radiation therapy aims to deliver high doses of radiation to target organs whilst simultaneously 
respecting the normal tolerance of surrounding tissues—that is, to eradicate the tumor while 
preserving the structure and function of other organs. Advances in radiation therapy, such as high-
energy linear accelerators, conformal radiation therapy (CRT) and intensity-modulated radiation 
therapy (IMRT), have allowed higher doses of radiation to be delivered to the tumor whilst sparing 
surrounding tissues. Despite these advances, tissue injury to non-target organs does still occur.2 
The aim of this Review is to accurately describe the pathophysiology, pathology, clinical presentation 
and management of late radiation cystitis. 
Pathophysiology 
The effects of radiation on a cellular level are twofold. A somatic effect is caused by radiolysis of 
water, resulting in the production of activated free oxygen radicals (hydroxyl and superoxide 
radicals). These highly reactive radicals cause lipid peroxidation, which induces cell membrane injury 
and immediate cell death. Genetic damage is caused directly by absorption of energy by DNA 
(according to target theory), as well as indirectly via reaction of DNA with oxygen radicals. This can 
lead to mutation and/or replication failure, and ultimately delayed cell death.1 
The radiosensitivity of different tissues varies, depending largely on their proliferative rate. Normal 
bladder epithelium has a low proliferative rate, and is thus sensitive to radiation. In general, 
intermediate and basal urothelial cells show signs of damage within 3 months of radiation exposure. 
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By 6–12 months, a radiation-dose-dependent increase in proliferative activity of the urothelium is 
usually evident. Tight junctions and the normal proteoglycan layer may be lost as a result of 
urothelial radiation injury, which interrupts the barrier between urine and bladder tissue. This 
correlates with the onset of irritative lower urinary tract symptoms that are commonly encountered 
after radiation therapy. Vascular endothelial cell edema also occurs early after radiation exposure 
(within 3 months), with endothelial cell proliferation seen >6 months after radiation. Additional signs 
of endothelial cell damage and perivascular fibrosis occur by 6–12 months, potentially resulting in 
vascular occlusion and focal bladder ischemia.3 
The smooth muscle of the urinary bladder is also sensitive to radiation. Edema occurs early and may 
be followed by cellular destruction. Normal smooth muscle may be replaced by fibroblasts, 
ultimately leading to increased collagen deposition. Such changes lead to decreased bladder 
compliance and functional changes in bladder capacity. Late bladder fibrosis is secondary to vascular 
ischemia. Thus, the target for late bladder damage seems to be vascular endothelial cells. Changes in 
endothelial cells are seen months to years following radiation therapy, and are not prominent at 
earlier time periods. Injury to the epithelial cell layer does not seem to have an important role in the 
development of late effects.3 
Pathology 
Acute radiation tissue injury to the bladder is caused primarily by damage to the bladder mucosa, 
which contains cells that divide rapidly. This usually occurs during the treatment period, and involves 
an acute inflammatory response and tissue edema.4 
The underlying pathology of late adverse effects is different from that seen in the acute reaction. 
Late-responding tissues, such as vascular and connective tissues, have a slow turnover rate; 
therefore, while they sustain radiation damage at the time of treatment, the effects are not 
expressed until repeated cell division is attempted.4 For this reason, late radiation tissue injury can 
take several months to many years to develop, and is largely a function of the total radiation dose 
and fraction size. The pathological hallmark of late radiation tissue injury is obliterative endarteritis 
resulting in atrophy and fibrosis. Tissue damaged by radiation is often referred to as “three-H tissue” 
(hypovascular, hypocellular and hypoxic). The capability to replace normal collagen and cell loss is 
compromised in hypoxic conditions, which results in tissue breakdown. This causes the bladder 
mucosa to become necrotic and slough off, leading to hematuria. Impaired healing under ischemic 
conditions can lead to ulcer and fistula formation. Telangiectasia (permanent dilation of blood 
vessels, usually in the mucous membranes) develops, and can also cause bleeding. Fibrosis forms 
part of the repair process and, if severe, can lead to a reduction in bladder capacity.3 
Clinical presentation 
Acute radiation cystitis occurs either during or shortly after radiation treatment. Symptoms 
experienced include dysuria and increased urinary frequency and urgency. This condition is usually 
self-limiting, and seldom persists for longer than 3 months after radiation therapy. Standard 
management is, therefore, conservative: symptomatic relief with the use of anticholinergic drugs 
(such as oxybutynin chloride) is usually sufficient. Alternative treatment options include 
phenazopyridine hydrochloride and flavoxate hydrochloride.3 
Late radiation cystitis following radiation therapy for cancers in the pelvic region has an incidence of 
5–10%. Levenback et al.5 reported an incidence of 6.5% in 1,784 patients with stage 1b cervical 
cancer treated with radiation therapy over a period of 29 years. Radiation cystitis is most common in 
patients with bladder cancer treated with radiation: in a review of 10-year survivors of bladder 
cancer treated with definitive radiation therapy, 10% of patients developed contracted bladders.6 
Other studies report incidences in the range of 2–47%.3 Late radiation cystitis can develop from at 
2
least 6 months to as long as 20 years after radiation treatment, with a mean latent period of 35 
months.5 
Several patient, tumor and treatment factors might increase the risk of developing late radiation 
cystitis. Pre-existing medical conditions, such as diabetes, hypertension and previous unrelated 
abdominal surgery, are important factors. Tumor stage determines the volume of tissue irradiated 
and the overall dose of radiation administered. Surgery, postoperative complications and 
chemotherapy are also important considerations in evaluating the baseline risk, and may contribute 
to the development of late radiation cystitis. Most important are factors related to the radiation 
treatment, including the volume of tissue treated, total bladder dose and fractionation, mode of 
delivery (external beam and/or brachytherapy), concurrent treatments and the radiosensitivity of the 
affected bladder tissue.3 
Hematuria is the main presenting symptom, and can vary from mild hematuria to life-threatening 
hemorrhage. Hematuria with clot formation can lead to urinary retention. Other lower urinary tract 
symptoms, including pain, increased urinary frequency and urgency, and incontinence, may also be 
present. 
Diagnosis 
The clinical features of late radiation cystitis are nonspecific, and can also be caused by bladder 
infection or malignancy. Thus, diagnosis is focused on the exclusion of other causes of hematuria. 
Dipstick urinalysis and urine culture are essential to exclude infection, and urine cytology is valuable 
to detect high-grade malignancy. Upper urinary tract evaluation in the form of ultrasonography or 
excretory urography is also recommended. Lower urinary tract evaluation in the form of cystoscopy 
is mandatory, and may reveal erythema, edema, telangiectasia, bleeding ulcers, fistulas or fibrosis 
with reduction in bladder capacity. At the time of cystoscopy, bladder biopsy may be performed if 
there is suspicion of tumor recurrence, with particular attention to the potential risk of perforation of 
the irradiated bladder wall. 
Grading 
The EORTC (European Organisation for Research and Treatment of Cancer) and RTOG (Radiation 
Therapy Oncology Group) have produced standardized scoring scales for uniform reporting of 
radiation toxicity in different target organs. These scales include four elements, representing 
subjective, objective, management and analytical (SOMA) evaluation of late effects to normal tissues 
(LENT). Each individual organ or tissue known to be within the target irradiation zone, and hence at 
risk of being damaged, has its own LENT-SOMA scale, which is based on the original RTOG criteria for 
radiation morbidity.7 
The LENT-SOMA scale is a comprehensive system and provides much information, but it is difficult to 
implement in routine practice outside of clinical studies.8 Instead, the severity of hematuria can be 
graded using both the RTOG/EORTC9 (Table 1) and NCI CTCAE (National Cancer Institute Common 
Terminology Criteria for Adverse Events)10 grading systems, which are probably of more practical use 
and are, therefore, more widely used in clinical practice. 
Management 
Initial management of late radiation cystitis includes resuscitation of the patient if necessary. If 
hemorrhagic shock is present, aggressive intravenous fluid replacement is required, and blood 
transfusion is indicated if the patient's hematocrit is low. A transurethral catheter should be inserted 
and intermittent or continuous bladder irrigation started, which is continued until the urine becomes 
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clear. Most patients will respond to conservative management; however, refractory cases will 
require alternative treatment options (Box 1), which are outlined below. 
Intravesical instillation 
A number of agents have been administered intravesically for the purpose of alleviating symptoms 
associated with late radiation cystitis. Although the mechanisms of action of these agents vary, the 
principles essentially include sterilization, lavage and arrest of focal bleeding points. 
Aluminum 
Aluminum salts, such as alum, are classified pharmacologically as astringents, and act by precipitating 
proteins on the cell surface and in interstitial spaces. This mechanism arrests capillary bleeding in 
mild cases, but in heavy bleeding the precipitant tends to clot, leading to clot retention, distension 
and more bleeding.11 Local adverse effects include suprapubic pain and vesical tenesmus, which can 
be controlled with antispasmodic and/or analgesic drugs.12 Encephalopathy has been reported in 
patients with renal failure, indicating that adequate renal function is essential for clearing a 
parenteral aluminum load.13 Complete response rates range from 50% to 100% (Table 2). In a 
retrospective series of seven patients with radiation cystitis and hematuria treated with 1% 
aluminum sulfate as an intravesical lavage, Octavio Castillo and Buizza14 reported good control of 
bleeding in all cases. 
Placental extract 
Placental extract is known to have a positive effect on the epithelialization of venous ulcers when 
applied topically, and, because of its wound-healing properties, has been used in the setting of 
radiation cystitis. Growth factors and angiogenic factors that have been isolated from the early 
placenta are thought to contribute to its healing effect on the mucosa. Micic and Genbacev15 
performed a prospective observational study of 21 patients with chronic radiation cystitis treated 
with early placental extract, who all had relief of their urinary symptoms at 15 months. Objective 
improvement in bladder mucosal appearance on cystoscopy was reported in 18 of 21 patients. No 
adverse effects were noted. 
Prostaglandins 
Three case studies have been reported in which patients were successfully treated with intravesical 
prostaglandins;16, 17, 18 however, whether the treatment results in these isolated reports were durable 
is not known. The protective mechanism of prostaglandins is probably mediated by increased cyclic 
AMP levels and stimulation of active sodium transport, with subsequent reductions in edema and the 
inflammatory response.4 
Formalin 
Formalin has been used in patients with severe radiation cystitis refractory to other treatment 
options.19, 20, 21, 22, 23, 24 Intravesical formalin instillation is performed under general or regional 
anesthesia once vesicoureteral reflux has been excluded. It causes precipitation of cellular proteins in 
the mucosa, producing an occlusive and fixative action on telangiectatic tissue and small capillaries. 
However, fixation of the bladder musculature may result in a small, contracted bladder, and fixation 
of the intramural ureter can also lead to obstruction with subsequent hydronephrosis and renal 
failure. Formalin is toxic even in very dilute (1%) solution, and a recognized adverse effect is reflux 
leading to bilateral pyonephrosis with fatal sepsis.21 Thus, it is recommended that intravesical 
formalin only be used when the bladder has been defunctioned by means of urinary diversion. 
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Dewan et al.21 reported on a retrospective series of 35 women with hemorrhagic radiation cystitis 
following radiation therapy for cervical cancer who were treated with 1% (n = 22), 2% (n = 10) or 4% 
(n = 4) intravesical formalin. After a single instillation, 31 patients (89%) achieved complete 
responses and 3 (8%) achieved partial responses. Minor complications were seen in 19 patients 
(54%), and major complications occurred in 11 patients (31%), 5 of whom required subsequent 
urinary diversion. One patient died of persistent bleeding and probable formalin toxicity. A 1% 
solution was as effective in controlling hematuria as higher concentrations, and was associated with 
significantly less morbidity. 
Donahue and Frank24 published a meta-analysis on the use of formalin as an intravesical agent in 235 
patients with intractable hemorrhagic cystitis. The overall complete response rates for 10%, 5% and 
1% formalin were 83%, 78% and 71%, respectively. Most patients responded within 48 h, and the 
response was durable for a mean of 3–4 months. Interestingly, of those whose disease recurred, only 
55% had a complete response to subsequent intravesical formalin instillation. 5% and 10% formalin 
solutions were associated with increased morbidity and mortality; however, higher formalin 
concentrations were required to control bleeding due to radiation cystitis compared with other 
causes of hemorrhage. 
Lowe and Stamey22 described a novel method of intravesical formalin use. This approach involves 
endoscopic topical placement of formalin-soaked pledgets on bleeding foci for a short period of time, 
and showed good results and minimal toxicity. Lojanapiwat et al.23 compared the outcomes of 11 
patients treated with a single intravesical 4% formalin instillation and 8 patients treated with 10% 
formalin-soaked pledgets placed on the bleeding points for 15 min; cessation of bleeding was 
achieved in 9 (82%) of 11 patients and 6 (75%) of 8 patients, respectively. These results suggest that 
topical application of formalin-soaked pledgets is as effective for controlling hemorrhage as 
conventional intravesical formalin instillation, and is associated with fewer complications. 
Studies of aluminum and formalin as intravesical agents used in the treatment of severe bladder 
hemorrhage (independent of the cause) are compared in Table 2. In summary, aluminum should be 
used as the first-line intravesical instillation agent to halt severe hematuria that does not respond to 
continuous bladder irrigation, as it has a high response rate (78–83%) and a more favorable toxicity 
profile than formalin. Intravesical formalin instillation has also been shown to be successful, with a 
meta-analysis reporting an overall complete response rate of 80%.22 Higher concentrations of 
formalin tend to produce better results, but with an increased toxicity profile. The use of placental 
extract and prostaglandins have been reported only in isolated cases, so cannot be recommended as 
part of the routine management of late hemorrhagic radiation cystitis. 
Systemic therapies 
Late radiation-induced changes in the bladder ultimately impair the function of the epithelium, which 
is then unable to maintain the integrity of the bladder–urine interface. Based on this principle, 
various agents have been administered systemically in order to enhance the protective 
polysaccharide layer (Table 3). 
Pentosan polysulfate 
Pentosan polysulfate is a semi-synthetic sulfated polysaccharide that serves as a synthetic 
glycosaminoglycan (GAG), and is thought to adhere to the bladder surface where it supplements the 
natural, defective GAG layer. Hampson and Woodhouse25 reported that 9 of 14 patients with 
hemorrhagic radiation cystitis achieved control of hematuria after treatment with oral sodium 
pentosan polysulfate. Sandhu et al.26 also recommended the use of oral sodium pentosan polysulfate 
as the primary method of managing hemorrhagic cystitis associated with pelvic radiation therapy, 
based on their experience with 51 patients, of whom 31 responded (21 had their dose reduced to a 
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maintenance dose and 10 stopped treatment). The results were durable after a median follow-up of 
450 days (range 19–4,526 days). No toxicities were reported, although 20 patients died from causes 
not related to hematuria. 
Conjugated estrogen 
Estrogens have been noted to have a beneficial effect in controlling hemorrhage in patients with late 
radiation cystitis by stabilizing vascular fragility. Liu et al.27 used conjugated estrogen in five patients 
unresponsive to other treatment options. Two patients received conjugated estrogen intravenously 
(1 mg/kg twice daily) for 2 days, and orally (5 mg once daily) thereafter. The other three patients 
received only conjugated estrogen orally (5 mg once daily). Four of the five patients experienced 
resolution of their symptoms for 12–22 months without adverse effects. 
WF10 
WF10 is a 1:10 dilution of tetrachlorodecaoxide formulated for intravenous delivery. Its 
pharmacologic actions include promotion of immune functions and tissue repair via the activation of 
macrophages. A multicenter, randomized, two-arm, open-label trial conducted by Veerasarn et al.28 
evaluated the efficacy and safety of WF10 as an adjunct to standard treatment in the management of 
late radiation cystitis compared with standard treatment alone. In the WF10 group, 37 of 50 patients 
showed complete resolution of objective hematuria, compared with 32 of 50 patients in the standard 
therapy group (P = 0.28). Significantly fewer responders in the WF10 group experienced recurrence 
of hematuria compared to the standard therapy arm (17 of 37 patients versus 24 of 32 patients, P = 
0.01). A phase II study by the same authors29 evaluated 16 patients with late radiation cystitis (grade 
2–3) treated with WF10. After completion of therapy, 14 patients had improvement to grade 0–1 
hematuria. At a median follow-up of 51 months, 4 of 14 patients had developed recurrent symptoms. 
Other interventions 
Cystoscopy with fulguration 
Cystoscopy with fulguration of bleeding points is an effective method of treating hemorrhagic cystitis 
that is unresponsive to conservative measures.5 This procedure can be performed under local 
anesthesia, especially in females. Methods of fulguration include the use of electrocoagulation, 
diathermy, and argon30 or neodymium-doped yttrium–aluminum–garnet laser.31 Potential morbidity 
following cystoscopy and fulguration includes bladder perforation with subsequent fistula 
formation.32 Cheng and Foo33 reported that more-severe cases of hemorrhagic cystitis often do not 
respond to this treatment modality. 
Botulinum toxin A 
Chuang et al.34 reported the use of 200 U botulinum toxin A injections in six patients with refractory 
radiation cystitis. Under sedation or local anesthesia, botulinum toxin A was submucosally injected 
through a cystoscope into 20 sites in the trigone and floor of the bladder. A moderate to significant 
improvement was achieved in five of the six patients, with mean bladder capacity increasing from 
105 ml to 250 ml and mean urinary frequency decreasing from 14 to 11 episodes per day. 
Orgotein 
Orgotein is an analog of the naturally occurring superoxide dismutase, and has been used in the 
treatment of radiation cystitis.35 The mechanism of late radiation-induced changes relates to the 
generation of free radicals, particularly the superoxide radical, which has a primary role in initiating 
and sustaining biologic damage and the growth of fibrotic tissue, and is responsible for the 
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production of other free radicals and lipoperoxidases. Superoxide dismutase catalyzes the 
destruction of these superoxide radicals. 
Marberger et al.35 reported on a retrospective series of 30 patients with late radiation cystitis treated 
with intramural orgotein injections. Clinical improvement in symptoms and cystoscopy findings were 
noted in 25 of the 30 patients. Its use as an alternative option in the routine management of late 
radiation cystitis, however, cannot be recommended, as no further studies have been reported in the 
literature. 
Surgical interventions 
More-aggressive treatment options include selective embolization or ligation of the iliac arteries.36 
Percutaneous embolization of both vesical arteries has also been described.37 Surgical options 
include urinary diversion with or without cystectomy, which should be considered a last resort. 
Reports suggest that a transverse colon conduit is the preferred method of urinary diversion,38 which 
has the advantage of using the nonirradiated bowel and ureters for creating the diversion. 
Alternative options for urinary diversion include percutaneous nephrostomy39, 40 and cutaneous 
ureterostomy.41 
Complications related to the defunctionalized bladder occur in more than 50% of patients who 
undergo urinary diversion,42 and include pyocystis, hemorrhage, pain and neoplastic 
transformation;43 therefore, cystectomy is recommended at the time of urinary diversion.44 
Preoperative high-dose radiation therapy contributes to increased postoperative morbidity rates, 
particularly enteroenteric fistulas, urointestinal fistulas and stenosis of the ureterointestinal 
anastomosis.45 Any alternative treatment options that are associated with less morbidity should be 
considered first before embarking on such debilitating surgery. 
Hyperbaric oxygen therapy 
Hyperbaric oxygen therapy (HBOT) involves the administration of 100% oxygen in a pressurized 
treatment chamber (Figure 1). The hyperbaric chamber provides conditions under which hemoglobin 
is fully saturated and oxygen is dissolved at very high concentrations in the blood plasma, which is 
then circulated to provide therapeutic benefits—such as increased angiogenesis and fibroblast 
activity46—in damaged tissues. Thus, it can be considered as an alternative treatment for patients 
with an underlying ischemic process that is unresponsive to conventional therapy. The degree of 
hyperoxygenation in HBOT cannot be achieved by any other means. 
HBOT has been proposed as a treatment option for patients with radiation cystitis that does not 
respond to conventional management, based on the rationale that it can correct ischemic injury 
secondary to radiation damage. A number of investigators have studied HBOT in this setting.47, 48, 49, 50, 
51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 An advantage of HBOT in these patients is the absence of the 
adverse effects on bladder structure or function that may be seen with other therapies, such as 
formalin or silver nitrate instillations, while avoiding the need for surgery. HBOT is also very well 
tolerated, with few adverse effects—the most common being pressure-related in the form of ear and 
sinus barotrauma. Serious complications, such as oxygen toxicity, are very rare.46 
The reported success rate of HBOT for radiation cystitis varies from 60% to 92% (Table 4). These 
results are highly in favor of this treatment option for refractory radiation-induced hemorrhagic 
cystitis. Various HBOT regimens have been used: in general, 100% oxygen is administered at 
pressures of 1.5–2.5 atm for 45–120 min, allowing extra time for compression and decompression. In 
addition, 5 min “air-breaks” can be introduced each half-hour to reduce the risk of oxygen toxicity. 
Sessions are administered once daily for a predetermined length of time (usually 20–30 sessions).65 
Bevers et al.55 reported the only prospective study of HBOT—a clinical trial with 40 patients seen at a 
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single center over an 8-year period. All patients received HBOT for refractory radiation-induced 
hemorrhagic cystitis, defined as persistent or recurrent symptoms despite one or more conventional 
treatments. The success rate was 92%: 30 patients had no recurrent bleeding within 3 months, 7 had 
a partial response with minimal bleeding, and only 3 had recurrent bleeding after a mean of 13.3 
months. The severity of the initial bleeding influenced the response to HBOT. Patients with mild to 
moderate symptoms had a 100% response rate, and in those with severe initial bleeding the 
response rate was 83%. Of the three patients with recurrent bleeding after successful HBOT, two had 
recurrent cancer, which is the most important factor associated with persistent hemorrhage after 
treatment. 
Chong et al.61 reported retrospectively on the outcomes of HBOT in 60 patients over a 13-year 
period. The results showed an 80% overall success rate, which increased to 96% in patients treated 
within 6 months of the onset of hematuria, suggesting an improved outcome if HBOT is commenced 
early. Prior treatment with intravesical installations did not affect the outcome of HBOT. Patients 
who had undergone primary, adjuvant or salvage radiation therapy showed equivalent response 
rates (81%, 83% and 78%, respectively). 
Del Pizzo et al.57 reported poor long-term results, with 8 of 11 patients ultimately requiring urinary 
diversion to achieve definitive control of their hematuria. At a median follow-up of 2.5 years, 8 
patients were asymptomatic and 3 required urinary diversion; however, at a median of 5.1 years, 5 of 
the 8 initially asymptomatic patients had episodes of delayed recurrent hematuria, which ultimately 
required urinary diversion as definitive therapy. This study highlights the progressive nature of 
radiation injury and the need for long-term follow-up before pronouncing that HBOT will be 
successful as a treatment for radiation cystitis. 
The Baromedical Research Foundation in South Carolina, USA, is currently conducting the HORTIS 
(Hyperbaric Oxygen Radiation Tissue Injury Study) project. The principal objective of this research is 
to precisely determine the degree of benefit that HBOT affords in the treatment of late radiation 
tissue injury. The study has eight components (HORTIS-I–VIII): seven involve evaluation of established 
radiation tissue injury at different anatomical sites (soft tissues, mandible, bladder, rectum, colon, 
gynecologic and larynx); the eighth will investigate the potential of prophylactic HBOT against 
radiation tissue injury.65 HORTIS-III is a multicenter, prospective, double-blind, randomized, sham-
controlled trial to evaluate the effectiveness of HBOT in patients with refractory radiation cystitis; 
these results are eagerly awaited.66 Clarke et al.67 reported the results of HORTIS-IV, which evaluated 
the effectiveness of HBOT in 120 patients with refractory radiation proctitis. Patients were 
randomized to undergo either HBOT at 2 atm (group 1) or air at 1.1 atm (group 2). The mean LENT-
SOMA score improved in both groups; however, the mean score was significantly lower (P = 0.015), 
and the amount of improvement nearly twice as great (5.00 versus 2.61, P = 0.0019), in group 1 
compared to group 2. Group 1 also had a greater portion of responders per clinical assessment than 
did group 2 (88.9% versus 62.5%, P = 0.00009). Thus, HBOT significantly improved the healing 
responses in patients with refractory radiation proctitis: at 5 years' follow-up (n = 14), there 
remained a clear trend towards continued and enduring healing. 
Management overview 
Initial management of patients with radiation cystitis includes intravenous fluid replacement and 
blood transfusion if required, followed by transurethral catheterization with bladder washout and 
irrigation. Most patients will respond to these measures; however, if conservative management fails, 
intravesical instillation of alum solution should be attempted. Intravesical instillation of dilute 
formalin has equivalent response rates, but is associated with a higher rate of complications. 
Cystoscopy with electrodiathermy or laser fulguration of bleeding points is sometimes effective. Oral 
or parenteral agents, such as pentosan polysulfate, conjugated estrogens or WF10, should not 
currently be considered as part of routine management. 
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Surgical options should only be considered as a last resort. These include selective embolization or 
ligation of internal iliac arteries, and urinary diversion (percutaneous nephrostomy, cutaneous 
ureterostomy or creation of bowel conduits using transverse colon or nonirradiated ileum) with 
cystectomy. HBOT can be used as an alternative to surgical management if available (Figure 2). 
Conclusions 
Radiation-induced tissue injury is categorized as either acute or late. Acute radiation injury to the 
bladder is usually self-limiting; however, late radiation cystitis, although relatively rare, can lead to 
severe hemorrhage and may be difficult to treat. Numerous treatment options have been studied 
over the past few decades, but many patients still ultimately require surgery to halt life-threatening 
hematuria. Surgery of this nature is often associated with significant morbidity, and any alternative 
treatment options should be explored further. 
The literature reveals compelling evidence in favor of HBOT as a treatment alternative for late 
radiation hemorrhagic cystitis refractory to conservative measures, although the majority of studies 
have been retrospective case series. A sufficiently powered, multicenter, prospective, double-blind, 
randomized, sham-controlled trial, such as HORTIS,66 is required to establish the true efficacy of 
HBOT. 
Review criteria 
A comprehensive PubMed search of the English-language literature published between January 1980 
and September 2009 was performed for relevant articles using the Medical Subject Heading (MeSH) 
terms “radiation cystitis”, “hemorrhagic cystitis” and “management” in various combinations. The 
reference lists of retrieved articles were assessed for additional articles. 
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Key points 
 Late radiation cystitis can cause severe, life-threatening hematuria 
 Oral or parenteral agents to control hematuria resulting from late 
radiation cystitis include conjugated estrogens, pentosan polysulfate and 
WF10 
 Intravesical agents that can be used include alum, placental extract, 
prostaglandins and formalin 
 Less-invasive interventions include cystoscopic fulguration of bleeding 
points, urinary diversion by percutaneous nephrostomy, and embolization 
of the internal iliac arteries 
 Surgical options include urinary diversion with or without cystectomy 
 Hyperbaric oxygen therapy has been reported to yield high success rates, 
with a low risk of complications 
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Box 1 Management options for radiation cystitis 
Acute radiation cystitis 
Phenazopyridine 
Flavoxate 
Anticholinergics (e.g. oxybutynin, terodiline) 
late hemorrhagic radiation cystitis 
Oral and intravenous hydration, with or without blood 
transfusion 
Bladder catheterization 
Intermittent or continuous bladder irrigation 
Oral or parenteral agents: 
 Hematinics (e.g. tranexamic acid) 
 Conjugated estrogens 
 Sodium pentosan polysulfate 
 WF10 (tetrachlorodecaoxide) 
 Pentoxifylline 
Cystoscopy, with or without: 
 Fulguration (electrodiathermy or laser) 
 Botulinum toxin A injection 
 Orgotein injection 
Intravesical instillation: 
 Alum (aluminum salts) 
 Silver nitrate 
 Placental extract 
 Prostaglandins 
 Formalin 
Surgery: 
 Selective embolization or ligation of internal iliac 
arteries 
 Urinary diversion: percutaneous nephrostomy, 
cutaneous ureterostomy or bowel conduit (transverse 
colon or nonirradiated ileum) 
 Cystectomy and urinary diversion 
Hyperbaric oxygen therapy 
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Figures 
 
 
Figure 1 Hyperbaric oxygen chambers 
a | Newly delivered hyperbaric chamber prior to installation. b | Hyperbaric oxygen chamber with 
control panel. 
 
 
Figure 2 Algorithm illustrating the recommended management of late hemorrhagic radiation cystitis 
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